US Colorectal Cancer Drugs Market Report 2023 to 2030

US Colorectal Cancer Drugs Market Analysis

$ 3999

US Colorectal Cancer drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for colorectal cancer drugs is expanding due to various reasons like increase incidence and prevalence of colorectal cancer cases, increase awareness about the disease, globally ageing population. Mortality due to colorectal cancer, rising medical tourism in developing countries and benefits offered by generic medicines are other reasons. Bristol-Myer Squibb, Merck, Sanofi, Eli Lilly, Bayer are the top key market players in Global Colorectal Cancer drugs Market.

ID: IN10USRD077 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Nipun Arora

Buy Now

US Colorectal Cancer Drugs Market Analysis Summary

US Colorectal Cancer Drugs Market is valued at around $5.74 Bn in 2022 and is projected to reach $6.77 Bn by 2030, exhibiting a CAGR of 2.1% during the forecast period 2023-2030.

The colorectal cancer drugs market includes all the drugs and therapies which are used to treat and manage colorectal cancer. Adjuvant/neoadjuvant medicines for treatment are also included in the market. Colorectal cancer (CRC) also known as Bowel cancer, affects the large intestine and the rectum. They are also called colon tumours or rectal cancer, depending on where they start. Vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators are the main categories of colorectal cancer medications. Drugs that inhibit the function of VEGF and VEGFR are known as vascular endothelial growth factors (VEGF). Chemotherapy, immunotherapy, and other medication groups are among them. Chemotherapy's market share is anticipated to decline due to its non-specificity, side effects, and the emergence of chemical agent resistance. Increasing use of targeted therapies and biologicals is going to be the new trend in the market. Hormone treatments, gene expression regulators, apoptosis-inducing agents, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules are examples of target therapies. Due to its selectivity towards cancer cells, while minimising harm to off-target cells, targeted therapy is becoming increasingly important. Instead of using chemical medications that weaken the body's immune system, biological therapy harnesses the body's immune system to fight cancer. Pharmaceutical and biotechnology firms like Eli Lilly and Company, Roche, Merck & Co., Pfizer, Sanofi, and Novartis, are some of the major players in the market.

Market Dynamics

Market Drivers

Colorectal cancer awareness- An increase in awareness about colorectal cancer and thus new product introductions are market-driving factors.

Rising Incidence and Prevalence- Colorectal cancer is one of the most widespread and costly cancers in the world. The need for colorectal cancer medications is driven by the rising incidence and prevalence of colorectal cancer, which results in a sizable patient population needing efficient therapies.

Globally ageing population- As the ageing population is increasing global incidence of colorectal cancer cases also increases.

Rising medical tourism in developing countries- Medical tourism is increasing in developing countries which is also increasing the market in these countries.

Mortality due to colorectal cancer – This increases the R and D in the development of new drugs.

Government initiatives and funding- Health organisations and governments all over the world are recognising the impact of colorectal cancer and the demand for better therapies. They are putting plans in place to increase knowledge, enhance early diagnosis, and give financing for colorectal cancer therapy research and development.

Benefits offered by generic drugs in colorectal cancer treatment are also a driving factor

Market Restraints

High development costs: New treatments require significant research, preclinical studies, and stringent clinical trials in colorectal drug development.

Increase use of biologicals and targeted therapies acts as a restraint for conventional chemotherapy drugs.

Key players

Merck & Co., Inc. Roche Holding AG Pfizer Inc. Bristol Myers Squibb Company Sanofi Genzyme AstraZeneca PLC Eli Lilly and Company Novartis AG AbbVie Inc. Taiho Oncology, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Colorectal Cancer Drugs Market

By Therapy:

Targeted therapy
Immunotherapy
Chemotherapy

By Cancer type:

Colorectal adenocarcinoma
Gastrointestinal carcinoid tumours
Others

By Distribution Channels:

Hospital pharmacies
Retail pharmacies
Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.